![Halina Offner](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Halina Offner
Fondateur chez Artielle ImmunoTherapeutics, Inc.
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Gilbert N. Miller | M | - |
Artielle ImmunoTherapeutics, Inc.
![]() Artielle ImmunoTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Artielle ImmunoTherapeutics, Inc. develops therapeutics for autoimmune diseases. Its Recombinant T-cell receptor Ligands can be tailored to target different illnesses. The company develops RTL1000, a compound for the treatment of multiple sclerosis. The company was founded by Halina Offner, Arthur Vandenbark and Gregory G. Burrows in 2004 and is headquartered in San Mateo, CA. | 23 ans |
Peter C. M. McWilliams | M | - |
Artielle ImmunoTherapeutics, Inc.
![]() Artielle ImmunoTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Artielle ImmunoTherapeutics, Inc. develops therapeutics for autoimmune diseases. Its Recombinant T-cell receptor Ligands can be tailored to target different illnesses. The company develops RTL1000, a compound for the treatment of multiple sclerosis. The company was founded by Halina Offner, Arthur Vandenbark and Gregory G. Burrows in 2004 and is headquartered in San Mateo, CA. | - |
Arthur A. Vandenbark | M | - |
Artielle ImmunoTherapeutics, Inc.
![]() Artielle ImmunoTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Artielle ImmunoTherapeutics, Inc. develops therapeutics for autoimmune diseases. Its Recombinant T-cell receptor Ligands can be tailored to target different illnesses. The company develops RTL1000, a compound for the treatment of multiple sclerosis. The company was founded by Halina Offner, Arthur Vandenbark and Gregory G. Burrows in 2004 and is headquartered in San Mateo, CA. | 20 ans |
Peter O. Kohler | M | 85 |
Oregon Health & Science University
| 36 ans |
Brock Metcalf | M | - |
Artielle ImmunoTherapeutics, Inc.
![]() Artielle ImmunoTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Artielle ImmunoTherapeutics, Inc. develops therapeutics for autoimmune diseases. Its Recombinant T-cell receptor Ligands can be tailored to target different illnesses. The company develops RTL1000, a compound for the treatment of multiple sclerosis. The company was founded by Halina Offner, Arthur Vandenbark and Gregory G. Burrows in 2004 and is headquartered in San Mateo, CA. | - |
Brian Druker | M | 68 |
Oregon Health & Science University
| 31 ans |
Rick L. Bentzinger | M | - |
Oregon Health & Science University
| 19 ans |
Vincent Price | M | 60 |
Oregon Health & Science University
| - |
Jessica Castle | M | - |
Oregon Health & Science University
| - |
Derick Vivier | M | - |
Oregon Health & Science University
| - |
Daisy Alva | F | - |
Oregon Health & Science University
| - |
Erik Brodt | M | - |
Oregon Health & Science University
| - |
Kristen Beiers-Jones | F | - |
Oregon Health & Science University
| - |
Michael C. Heinrich | M | - |
Oregon Health & Science University
| - |
Rose McPharlin | F | - |
Oregon Health & Science University
| - |
Stefanie Petrie | F | - |
Oregon Health & Science University
| - |
Dennis Koop | M | - |
Oregon Health & Science University
| - |
Aaron Nilsen | M | - |
Oregon Health & Science University
| - |
Lev Fedorov | M | - |
Oregon Health & Science University
| - |
Kellie Guentert | F | - |
Oregon Health & Science University
| - |
Cary O. Harding | M | - |
Oregon Health & Science University
| 25 ans |
Misha Pavel | M | - |
Oregon Health & Science University
| - |
Tomasz Beer | M | - |
Oregon Health & Science University
| - |
Matthew C. Riddle | M | - |
Oregon Health & Science University
| - |
David E. Battaglia | M | - |
Oregon Health & Science University
| - |
Holly Jimison | M | - |
Oregon Health & Science University
| - |
Nancy Press | M | - |
Oregon Health & Science University
| - |
Yong Hong Yan | M | 57 |
Oregon Health & Science University
| - |
Shahab Fatheazam | M | 72 |
Artielle ImmunoTherapeutics, Inc.
![]() Artielle ImmunoTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Artielle ImmunoTherapeutics, Inc. develops therapeutics for autoimmune diseases. Its Recombinant T-cell receptor Ligands can be tailored to target different illnesses. The company develops RTL1000, a compound for the treatment of multiple sclerosis. The company was founded by Halina Offner, Arthur Vandenbark and Gregory G. Burrows in 2004 and is headquartered in San Mateo, CA. | 20 ans |
Christopher Dubay | M | - |
Oregon Health & Science University
| - |
Erwin Schwarz | M | - |
Oregon Health & Science University
| 25 ans |
William Thoma | M | - |
Oregon Health & Science University
| - |
Mary H. Oldshue | F | 72 |
Oregon Health & Science University
| - |
Michael McLean | M | - |
Oregon Health & Science University
| - |
Rocky Dixon | M | - |
Oregon Health & Science University
| - |
Henry Hollis Hewitt | M | 82 |
Oregon Health & Science University
| - |
Chad Waite | M | 69 |
Oregon Health & Science University
| - |
Scott Hansen | M | - |
Oregon Health & Science University
| - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Adolph J. Ferro | M | - |
Artielle ImmunoTherapeutics, Inc.
![]() Artielle ImmunoTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Artielle ImmunoTherapeutics, Inc. develops therapeutics for autoimmune diseases. Its Recombinant T-cell receptor Ligands can be tailored to target different illnesses. The company develops RTL1000, a compound for the treatment of multiple sclerosis. The company was founded by Halina Offner, Arthur Vandenbark and Gregory G. Burrows in 2004 and is headquartered in San Mateo, CA. | - |
Gregory G. Burrows | M | - |
Artielle ImmunoTherapeutics, Inc.
![]() Artielle ImmunoTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Artielle ImmunoTherapeutics, Inc. develops therapeutics for autoimmune diseases. Its Recombinant T-cell receptor Ligands can be tailored to target different illnesses. The company develops RTL1000, a compound for the treatment of multiple sclerosis. The company was founded by Halina Offner, Arthur Vandenbark and Gregory G. Burrows in 2004 and is headquartered in San Mateo, CA. | - |
Andrew S. Goldstein | M | - |
Artielle ImmunoTherapeutics, Inc.
![]() Artielle ImmunoTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Artielle ImmunoTherapeutics, Inc. develops therapeutics for autoimmune diseases. Its Recombinant T-cell receptor Ligands can be tailored to target different illnesses. The company develops RTL1000, a compound for the treatment of multiple sclerosis. The company was founded by Halina Offner, Arthur Vandenbark and Gregory G. Burrows in 2004 and is headquartered in San Mateo, CA. | 5 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 41 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Halina Offner
- Réseau Personnel